Alterations of Thymus-Derived Tregs in Multiple Sclerosis

Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200251. doi: 10.1212/NXI.0000000000200251. Epub 2024 Jun 4.

Abstract

Background and objectives: Multiple sclerosis (MS) is considered a prototypic autoimmune disease of the CNS. It is the leading cause of chronic neurologic disability in young adults. Proinflammatory B cells and autoreactive T cells both play important roles in its pathogenesis. We aimed to study alterations of regulatory T cells (Tregs), which likely also contribute to the disease, but their involvement is less clear.

Methods: By combining multiple experimental approaches, we examined the Treg compartments in 41 patients with relapsing-remitting MS and 17 healthy donors.

Results: Patients with MS showed a reduced frequency of CD4+ T cells and Foxp3+ Tregs and age-dependent alterations of Treg subsets. Treg suppressive function was compromised in patients, who were treated with natalizumab, while it was unaffected in untreated and anti-CD20-treated patients. The changes in natalizumab-treated patients included increased proinflammatory cytokines and an altered transcriptome in thymus-derived (t)-Tregs, but not in peripheral (p)-Tregs.

Discussion: Treg dysfunction in patients with MS might be related to an altered transcriptome of t-Tregs and a proinflammatory environment. Our findings contribute to a better understanding of Tregs and their subtypes in MS.

MeSH terms

  • Adult
  • Female
  • Humans
  • Immunologic Factors / pharmacology
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / immunology
  • Natalizumab* / pharmacology
  • T-Lymphocytes, Regulatory* / immunology
  • Thymus Gland / immunology
  • Young Adult

Substances

  • Natalizumab
  • Immunologic Factors